Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company is seeing record numbers as they release its 3rd quarter financial numbers. Saviuk told Proactive the company saw record revenues of 6.1 million in Q3 which was a 27% increase over Q2-22. Grose Margins also set a news record with a 34% increase over Q2. Saviuk is also projecting Q4 revenues to exceed $11 million dollars led by products XIIDRA, SIMBRINZA and ALLERJECT. Saviuk also shared with Proactive the company has entered into a deal to commerlize the drug Sabizabulin for COVID-19. Sabizabulin is an antiviral targeted for the treatment of hospitalized moderate-severe COVID-19 patients.
Valeo Pharma releases 3rd quarter financials showing records in Revenue and Gross Margins
